BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23480797)

  • 1. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer.
    Hart M; Wach S; Nolte E; Szczyrba J; Menon R; Taubert H; Hartmann A; Stoehr R; Wieland W; Grässer FA; Wullich B
    FEBS J; 2013 May; 280(9):2105-16. PubMed ID: 23480797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
    Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
    Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
    Kao CJ; Martiniez A; Shi XB; Yang J; Evans CP; Dobi A; deVere White RW; Kung HJ
    Oncogene; 2014 May; 33(19):2495-503. PubMed ID: 23728339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
    Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
    Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1.
    Lee KH; Lin FC; Hsu TI; Lin JT; Guo JH; Tsai CH; Lee YC; Lee YC; Chen CL; Hsiao M; Lu PJ
    Biochim Biophys Acta; 2014 Sep; 1843(9):2055-66. PubMed ID: 24915000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
    Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
    Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-204 is dysregulated in metastatic prostate cancer in vitro.
    Todorova K; Metodiev MV; Metodieva G; Zasheva D; Mincheff M; Hayrabedyan S
    Mol Carcinog; 2016 Feb; 55(2):131-47. PubMed ID: 25630658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
    Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
    Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells.
    Wang C; Tao W; Ni S; Chen Q; Zhao Z; Ma L; Fu Y; Jiao Z
    Cancer Sci; 2015 Apr; 106(4):375-82. PubMed ID: 25645686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
    Zammarchi F; Boutsalis G; Cartegni L
    PLoS One; 2013; 8(3):e49721. PubMed ID: 23472063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
    Shao L; Tekedereli I; Wang J; Yuca E; Tsang S; Sood A; Lopez-Berestein G; Ozpolat B; Ittmann M
    Clin Cancer Res; 2012 Dec; 18(24):6648-57. PubMed ID: 23052253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
    Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
    Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
    de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
    Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
    Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
    PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI.
    Zhu M; Chen Q; Liu X; Sun Q; Zhao X; Deng R; Wang Y; Huang J; Xu M; Yan J; Yu J
    FEBS J; 2014 Aug; 281(16):3766-75. PubMed ID: 24988946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.